Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

82.85
+0.09000.11%
Post-market: 82.79-0.0600-0.07%19:30 EDT
Volume:1.34M
Turnover:111.78M
Market Cap:11.67B
PE:-36.28
High:85.98
Open:83.75
Low:82.36
Close:82.76
52wk High:95.49
52wk Low:28.12
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.80
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:25.07
PE(LYR):-6,794.88

Loading ...

Arrowhead Pharmaceuticals - Madrigal to Pay $25 Mln Upfront and up to $975 Mln in Milestones to Arrowhead

THOMSON REUTERS
·
May 05

Arrowhead Pharmaceuticals - Eligible for Tiered Royalties on Commercial Sales

THOMSON REUTERS
·
May 05

Arrowhead licenses ARO-PNPLA3 MASH drug to Madrigal for USD 25 million upfront

Reuters
·
May 05

Arrowhead Pharmaceuticals to present at BofA Securities 2026 Healthcare Conference

Reuters
·
May 04

Arrowhead Pharmaceuticals Initiated at Overweight by JP Morgan

Dow Jones
·
May 01

Arrowhead says Australia TGA approves REDEMPLO for familial chylomicronemia syndrome

Reuters
·
May 01

Arrowhead Pharmaceuticals Receives Tga Approval of Redemplo® (Plozasiran) in Australia, Expanding Global Access for Patients With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
May 01

Arrowhead Pharmaceuticals - Phase 3 Study Shows Redemplo Reduces Triglycerides by Median 80% From Baseline

THOMSON REUTERS
·
May 01

JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target

MT Newswires Live
·
May 01

Arrowhead Pharmaceuticals : JP Morgan Initiates Coverage With Overweight Rating; Target Price $88

THOMSON REUTERS
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153%, and institutional views are bullish

Earnings Agent
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153.09%, and institutional views are bullish

Earnings Agent
·
May 01

A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS

Simply Wall St.
·
Apr 28

Arrowhead, Astera, Exxon, Intel, Halliburton Trending With Analysts

TIPRANKS
·
Apr 25

Arrowhead CFO Daniel Joseph Apel disposes of common shares worth $921,276

Reuters
·
Apr 25

Arrowhead CMO James Hamilton disposes of 10,000 shares worth $750,000

Reuters
·
Apr 25

Arrowhead says CHMP backs EU approval of REDEMPLO for familial chylomicronemia syndrome

Reuters
·
Apr 24

Arrowhead Pharmaceuticals - Receives Positive Chmp Opinion for Redemplo (Plozasiran) in Fcs in Europe

THOMSON REUTERS
·
Apr 24

Arrowhead Pharmaceuticals - European Commission Decision on Redemplo Marketing Authorization Expected in Q2 2026

THOMSON REUTERS
·
Apr 24

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. -- Barrons.com

Dow Jones
·
Apr 21